Picture supply: Getty Pictures
Airtel Africa (LSE: AAF) is the top-performing FTSE 100 inventory in my portfolio at present and it’s already gained an extra 10% this month.
One other one among my favourites, albeit nowhere close to the highest, is GSK (LSE: GSK). After months of declines, the healthcare group has been making a restoration. It’s up a powerful 11.6% over the previous month.
They’re very completely different corporations however each provide distinctive qualities, every serving to to bolster my portfolio in their very own manner.
An surprising development alternative
As an investor who prefers the security of defensive earnings shares, Airtel Africa is an odd selection for me. The telecoms supplier operates in what many would contemplate dangerous areas on the African continent.
Nonetheless, the danger has paid off. Up virtually 200% prior to now 12 months, the inventory is outshining even the biggest S&P 500 tech giants in my portfolio.
Sadly, the expansion is probably not sustainable. The current surge appears largely as a result of easing foreign money trade pressures and tariff will increase in Nigeria. Those self same pressures may simply flip again within the different path in such a unstable area. That’s a key threat I have to regulate.
Nonetheless, robust financials are backing among the development. Half-year income rose about 26% to almost $3bn, whereas revenue after tax climbed to $376m. With a quickly increasing community, rising margins and rising dividends, it appears to be heading in a superb path.
The worth could also be a bit overvalued now but it surely’s nonetheless value contemplating for its long-term prospects in Africa.
Resilient healthcare
GSK has recovered 38% after hitting a 52-week low on April’s commerce tariff information. It’s now only some pennies away from its five-year excessive of 1,800p achieved in Could 2024.
The biotechnology agency’s worth was boosted by a powerful set of third-quarter outcomes and an improved outlook for 2025. The corporate reported gross sales of £8.5bn, up round 7% 12 months on 12 months, with notably robust efficiency from its Speciality Medicines division, which grew 16% to £3.4bn.
Its oncology gross sales had been a standout success, surging practically 39%. That shines a lightweight on the rising energy of its new drug portfolio after offloading its prescription drugs arm.
The efficiency is supported by encouraging medical updates, notably for its respiratory biologics and RSV vaccine.
However I didn’t purchase GSK shares for his or her development prospects. They’re meant so as to add defensiveness to my portfolio, together with a good little bit of earnings from the three.6% dividend yield.
Whereas the expansion is welcome, historical past reveals that the inventory is extremely cyclical and can probably dip once more within the coming 12 months. Nonetheless, for earnings and defensiveness, it’s a worthy consideration, in my e-book.
Closing ideas
It’s unimaginable to precisely predict the path of shares. At instances, I’ve been pleasantly shocked, at others, I’ve been sadly dissatisfied.
That’s why I preserve a extremely diversified portfolio of shares from a variety of industries. These two have accomplished effectively this month however may simply slip within the subsequent.
Nonetheless, general, my portfolio usually enjoys regular development as every sector and inventory performs its half.
